Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.
The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.
Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.
Changes in depression symptoms over time are associated with differences in survival among patients with lung cancer, especially those with early stage disease.
Patient understanding of lung cancer screening increased after participation in focus groups.
IMRT was associated with lower rates of severe pneumonitis and cardiac doses compared with 3D-CRT in patients with locally advanced NSCLC.
An analysis of population trends in England demonstrated that use of electronic cigarettes improves the rate of successful quit attempts, but results in less use of prescription nicotine-replacement therapy products.
Adding WBRT to dexamethasone and best supportive care provides little additional benefit for patients with NSCLC and brain metastases who are ineligible to undergo resection or stereotactic radiotherapy.
The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.
Hypoxia-activated prodrugs prevented treatment resistance in a mathematical model of EGFR mutation-driven non-small cell lung cancer (NSCLC).
When patients ask about safety and using e-cigarettes to stop smoking, doctors give varying advice.
Longer overall survival was achieved with TKIs targeting EGFR mutations in non-small cell lung cancer (NSCLC) patients.
Pneumonitis related to the use of PD-1 inhibitor therapy is higher among patients with NSCLC and RCC, and during combination therapy.
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
A Systematic Review and Meta-analysis of the Risk of Diarrhea Associated With Vandetanib Treatment in Carcinoma PatientsJuly 21, 2016
[OncoTargets and Therapy] This research examines overall risks of all-grade and high-grade diarrhea during vandetanib treatment, to gain a better understanding of its prediction and management.
For nonsolid nodules identified by CT screening for lung cancer, annual screening with low-dose CT can eliminate the need for biopsy or surgery.
Lung cancers that manifest as nonsolid nodules seem to have indolent course, according to recent research data.
Findings suggest a possible increase in the risk of oral disease caused by e-cigarette use.
Undergoing pleurectomy and decortication for malignant pleural mesothelioma generally leads to improved quality of life after the surgery.
Breath analysis offers an option for both primary screening and postsurgery monitoring of patients with lung cancer. Exhaled breath has certain carbonyl VOCs that indicate the presence of lung cancer in a process researchers hope will receive FDA approval.
Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.
Fourteen percent to 25% of patients with lung cancer also have autoimmune disease. This comorbidity could make them unsuitable candidates for immunotherapy.
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.
Cigarette smoking is more common among survivors of AYA cancer than those without cancer, and smoking is associated with greater comorbidities and poorer general health.
Biochemical Marker Is a Better Predictor of Adverse Effects in Patients with Non-small Cell Lung CancerJune 13, 2016
Albumin concentration with an established cutoff point is proven a better predictor of both chemotherapy toxicity and survival in patients with advanced lung cancer.
Most family physicians report discussing low-dose CT imaging with patients at high risk for lung cancer, but referrals for screening remain low, a study published in the journal Cancer has shown.
Stepped care is effective and reduces recovery time among patients with head and neck cancer or lung cancer and untreated psychological distress.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|